The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...